Matches in SemOpenAlex for { <https://semopenalex.org/work/W2559412569> ?p ?o ?g. }
- W2559412569 endingPage "127" @default.
- W2559412569 startingPage "127" @default.
- W2559412569 abstract "In the context of contemporary pharmacotherapy, optimal antiplatelet management with percutaneous coronary intervention (PCI) has not been well established.To compare the ischemic and bleeding risks associated with glycoprotein IIb/IIIa inhibitors (GPIs) and a potent P2Y12 antagonist, cangrelor, in patients undergoing PCI.An exploratory analysis of pooled patient-level data from the 3 phase 3 Cangrelor vs Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PCI, CHAMPION PLATFORM, and CHAMPION PHOENIX) trials of patients undergoing elective or nonelective PCI. The participants included 10 929 patients assigned to cangrelor but not receiving GPIs (cangrelor alone) and 1211 patients assigned to clopidogrel (or placebo) and receiving routine GPIs (clopidogrel-GPI). Patients requiring bailout or rescue GPI therapy were excluded. To account for risk imbalances, 1:1 propensity score matching based on 16 baseline clinical variables yielded 1021 unique matched pairs. The present study's data analysis was conducted from October 28, 2015, to August 6, 2016.The primary efficacy end point was the composite of all-cause mortality, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 hours. Safety was assessed by 3 validated bleeding scales (Global Use of Strategies to Open Occluded Coronary Arteries [GUSTO], Thrombolysis in Myocardial Infarction [TIMI], and Acute Catheterization and Urgent Intervention Triage) and requirement for blood transfusions.Of the 12 140 patients included in the analysis, 8779 were men (72.3%), and the mean (SD) age was 63.2 (11.3) years. Patients in the clopidogrel-GPI group were more likely to be male (75.6% vs 71.9%), younger (median, 60 [range, 23-91] years vs 64 [range, 26-95] years), enrolled from the United States (77.9% vs 40.0%), and present with an acute coronary syndrome, but they had lower comorbid disease burden and were less likely to receive bivalirudin (8.8% vs 27.3%). In the matched cohorts, the rates of the primary efficacy end point were not significantly different between the cangrelor alone and clopidogrel-GPI groups (2.6% vs 3.3%; odds ratio [OR], 0.79; 95% CI, 0.48-1.32). There was a nonsignificant trend toward lower rates of GUSTO-defined severe/life-threatening bleeding with cangrelor alone compared with clopidogrel-GPI (0.3% vs 0.7%; OR, 0.43; 95% CI, 0.11-1.66). Rates of TIMI-defined major or minor bleeding were significantly lower in patients treated with cangrelor alone (0.7% vs 2.4%; OR, 0.29; 95% CI, 0.13-0.68).Based on a pooled analysis from the 3 phase 3 CHAMPION trials, cangrelor alone was associated with similar ischemic risk and lower risk-adjusted bleeding risk compared with clopidogrel-GPIs.clinicaltrials.gov Identifiers: NCT00305162, NCT00385138, and NCT01156571." @default.
- W2559412569 created "2016-12-08" @default.
- W2559412569 creator A5003831287 @default.
- W2559412569 creator A5007026783 @default.
- W2559412569 creator A5010936003 @default.
- W2559412569 creator A5026004870 @default.
- W2559412569 creator A5039432822 @default.
- W2559412569 creator A5046629853 @default.
- W2559412569 creator A5054649109 @default.
- W2559412569 creator A5060370891 @default.
- W2559412569 creator A5061881316 @default.
- W2559412569 creator A5062843291 @default.
- W2559412569 creator A5065347832 @default.
- W2559412569 creator A5069820090 @default.
- W2559412569 creator A5086306721 @default.
- W2559412569 creator A5087020318 @default.
- W2559412569 date "2017-02-01" @default.
- W2559412569 modified "2023-10-13" @default.
- W2559412569 title "Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors" @default.
- W2559412569 cites W133624405 @default.
- W2559412569 cites W1504071065 @default.
- W2559412569 cites W152096358 @default.
- W2559412569 cites W1538704194 @default.
- W2559412569 cites W1596397105 @default.
- W2559412569 cites W165703145 @default.
- W2559412569 cites W1978591428 @default.
- W2559412569 cites W1991096813 @default.
- W2559412569 cites W1994685505 @default.
- W2559412569 cites W1995259829 @default.
- W2559412569 cites W2000991311 @default.
- W2559412569 cites W2002479555 @default.
- W2559412569 cites W20146419 @default.
- W2559412569 cites W2016382632 @default.
- W2559412569 cites W2031081426 @default.
- W2559412569 cites W2039578887 @default.
- W2559412569 cites W2046794276 @default.
- W2559412569 cites W2071686230 @default.
- W2559412569 cites W2077401512 @default.
- W2559412569 cites W2078644068 @default.
- W2559412569 cites W2079311486 @default.
- W2559412569 cites W2087150869 @default.
- W2559412569 cites W2093117607 @default.
- W2559412569 cites W2099409915 @default.
- W2559412569 cites W2100321613 @default.
- W2559412569 cites W2111440117 @default.
- W2559412569 cites W2123112974 @default.
- W2559412569 cites W2127525777 @default.
- W2559412569 cites W2136228924 @default.
- W2559412569 cites W2140501627 @default.
- W2559412569 cites W2142552433 @default.
- W2559412569 cites W2142825093 @default.
- W2559412569 cites W2146338929 @default.
- W2559412569 cites W2147339594 @default.
- W2559412569 cites W2150655309 @default.
- W2559412569 cites W2154783291 @default.
- W2559412569 cites W2156927593 @default.
- W2559412569 cites W2201855454 @default.
- W2559412569 cites W2202462936 @default.
- W2559412569 cites W2260370392 @default.
- W2559412569 cites W2279877846 @default.
- W2559412569 cites W2395993059 @default.
- W2559412569 cites W2430995757 @default.
- W2559412569 cites W43843458 @default.
- W2559412569 doi "https://doi.org/10.1001/jamacardio.2016.4556" @default.
- W2559412569 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27902833" @default.
- W2559412569 hasPublicationYear "2017" @default.
- W2559412569 type Work @default.
- W2559412569 sameAs 2559412569 @default.
- W2559412569 citedByCount "36" @default.
- W2559412569 countsByYear W25594125692017 @default.
- W2559412569 countsByYear W25594125692018 @default.
- W2559412569 countsByYear W25594125692019 @default.
- W2559412569 countsByYear W25594125692020 @default.
- W2559412569 countsByYear W25594125692021 @default.
- W2559412569 countsByYear W25594125692022 @default.
- W2559412569 countsByYear W25594125692023 @default.
- W2559412569 crossrefType "journal-article" @default.
- W2559412569 hasAuthorship W2559412569A5003831287 @default.
- W2559412569 hasAuthorship W2559412569A5007026783 @default.
- W2559412569 hasAuthorship W2559412569A5010936003 @default.
- W2559412569 hasAuthorship W2559412569A5026004870 @default.
- W2559412569 hasAuthorship W2559412569A5039432822 @default.
- W2559412569 hasAuthorship W2559412569A5046629853 @default.
- W2559412569 hasAuthorship W2559412569A5054649109 @default.
- W2559412569 hasAuthorship W2559412569A5060370891 @default.
- W2559412569 hasAuthorship W2559412569A5061881316 @default.
- W2559412569 hasAuthorship W2559412569A5062843291 @default.
- W2559412569 hasAuthorship W2559412569A5065347832 @default.
- W2559412569 hasAuthorship W2559412569A5069820090 @default.
- W2559412569 hasAuthorship W2559412569A5086306721 @default.
- W2559412569 hasAuthorship W2559412569A5087020318 @default.
- W2559412569 hasBestOaLocation W25594125691 @default.
- W2559412569 hasConcept C126322002 @default.
- W2559412569 hasConcept C151730666 @default.
- W2559412569 hasConcept C164705383 @default.
- W2559412569 hasConcept C2776708134 @default.
- W2559412569 hasConcept C2777628954 @default.
- W2559412569 hasConcept C2777849778 @default.